M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 18 of 54

ACTIVE NOT RECRUITING Phase 2

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

NCT03074513
ACTIVE NOT RECRUITING Phase 2

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

NCT02983578
ACTIVE NOT RECRUITING Phase 2

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

NCT02912312
ACTIVE NOT RECRUITING Phase 2

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

NCT02816021
ACTIVE NOT RECRUITING Phase 2

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

NCT02960555
ACTIVE NOT RECRUITING Phase 2

Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors

NCT03035409
ACTIVE NOT RECRUITING Phase 2

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

NCT02846623
ACTIVE NOT RECRUITING Phase 2

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

NCT02971748
ACTIVE NOT RECRUITING NA

Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families

NCT04125914
ACTIVE NOT RECRUITING

Comprehensive Nutritional Geriatric Assessments in Identifying Malnutrition in Older Cancer Participants

NCT03035604
ACTIVE NOT RECRUITING Phase 2

Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases

NCT03028337
ACTIVE NOT RECRUITING Phase 1

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

NCT03028311
ACTIVE NOT RECRUITING Phase 1

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

NCT02696993
ACTIVE NOT RECRUITING Phase 2

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

NCT02910700
ACTIVE NOT RECRUITING Phase 2

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

NCT02884648
ACTIVE NOT RECRUITING

Expectations Regarding Mobility and Self-Care

NCT02911064
ACTIVE NOT RECRUITING

Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)

NCT02515383
ACTIVE NOT RECRUITING Early Phase 1

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

NCT02744053
ACTIVE NOT RECRUITING NA

Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers

NCT02774759
ACTIVE NOT RECRUITING Phase 2

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

NCT02876107
ACTIVE NOT RECRUITING Phase 2

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

NCT02754752
ACTIVE NOT RECRUITING NA

Supervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer

NCT02893397
ACTIVE NOT RECRUITING Phase 2

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

NCT02713269
ACTIVE NOT RECRUITING Phase 2

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

NCT02721732
ACTIVE NOT RECRUITING NA

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

NCT02697227
ACTIVE NOT RECRUITING Phase 2

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

NCT02861417
ACTIVE NOT RECRUITING NA

The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial

NCT02843425
ACTIVE NOT RECRUITING Early Phase 1

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

NCT02603887
ACTIVE NOT RECRUITING NA

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

NCT02698254
ACTIVE NOT RECRUITING Phase 2

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

NCT02756897
ACTIVE NOT RECRUITING Phase 1

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

NCT02726997
ACTIVE NOT RECRUITING Phase 1

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02321501
ACTIVE NOT RECRUITING NA

Tu Salud Si Cuenta Intervention in Increasing Physical Activity and Healthy Eating Among Latino Families

NCT03199365
ACTIVE NOT RECRUITING NA

Your Health Matters! (Tu Salud ¡Si Cuenta!): Promoting Healthy Lifestyles in Latino Families

NCT03199209
ACTIVE NOT RECRUITING Early Phase 1

Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders

NCT02790853
ACTIVE NOT RECRUITING Phase 2

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02703623
ACTIVE NOT RECRUITING Phase 1

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

NCT02668770
ACTIVE NOT RECRUITING Phase 1

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

NCT02600949
ACTIVE NOT RECRUITING NA

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

NCT02760849
ACTIVE NOT RECRUITING NA

Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer

NCT03085043
ACTIVE NOT RECRUITING Phase 2

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

NCT02629809
ACTIVE NOT RECRUITING NA

Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy

NCT05049746
ACTIVE NOT RECRUITING Phase 2

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

NCT02689440
ACTIVE NOT RECRUITING Phase 1

Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function

NCT02626312
ACTIVE NOT RECRUITING Early Phase 1

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02659241
ACTIVE NOT RECRUITING NA

Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy

NCT02662907
ACTIVE NOT RECRUITING Phase 2

MPDL3280A With Chemoradiation for Lung Cancer

NCT02525757
ACTIVE NOT RECRUITING Phase 4

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

NCT02162849
ACTIVE NOT RECRUITING NA

Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy

NCT02615275
ACTIVE NOT RECRUITING NA

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443
← Previous Page 18 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.